The U.S. Drug Enforcement Administration has been cracking down on synthetic drugs since they began gaining popularity in 2010. But because each newly designed drug needs to be separately banned through a "clunky and cumbersome" process, the problem continues to spiral, DEA head Chuck Rosenberg told a U.S. Senate committee.
Read Full Article »
